1	COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant,
2	and implications for vaccination
3	Wan Yang <sup>1*</sup> and Jeffrey Shaman <sup>2</sup>
4	<sup>1</sup> Department of Epidemiology, <sup>2</sup> Department of Environmental Health Sciences, Mailman School
5	of Public Health, Columbia University, New York, NY, USA
6	*Correspondence to: wy2202@cumc.columbia.edu
7	
8	Abstract
9	Background: The COVID-19 Delta pandemic wave in India surged and declined within 3
10	months; cases then remained low despite the continued spread of Delta elsewhere. Here we
11	aim to estimate key epidemiological characteristics of the Delta variant based on data from
12	India and examine the underpinnings of its dynamics.
13	
14	Methods: We utilize multiple datasets and model-inference methods to reconstruct COVID-19
15	pandemic dynamics in India during March 2020 – June 2021. We further use model estimates to
16	retrospectively predict cases and deaths during July – mid-Oct 2021, under various vaccination
17	and vaccine effectiveness (VE) settings to estimate the impact of vaccination and VE for non-
18	Delta-infection recoverees.
19	
20	Findings: We estimate that Delta escaped immunity in 34.6% (95% CI: 0 – 64.2%) of individuals
21	with prior wildtype infection and was 57.0% (95% CI: 37.9 – 75.6%) more infectious than
22	wildtype SARS-CoV-2. Models assuming higher VE among those with prior non-Delta infection,
23	particularly after the 1 <sup>st</sup> dose, generated more accurate predictions than those assuming no
24	such increases (best-performing VE setting: 90/95% vs. 30/67% baseline for the 1 <sup>st</sup> /2 <sup>nd</sup> dose).
25	Counterfactual modeling indicates that high vaccination coverage for 1 <sup>st</sup> vaccine-dose in India
26	(~50% by mid-Oct 2021) combined with the boosting of VE among recoverees averted around
27	60% of infections during July – mid-Oct 2021.
28	

29 Interpretation: Non-pharmaceutical interventions, infection seasonality, and high coverage of 30 1-dose vaccination likely all contributed to pandemic dynamics in India during 2021. Given the 31 shortage of COVID-19 vaccines globally and boosting of VE, for populations with high prior 32 infection rates, prioritizing the first vaccine-dose may protect more people. 33 34 **Key words:** COVID-19; Delta SARS-CoV-2 variant; India; vaccination effectiveness; boosting; 35 prior infection 36 37 Research in context 38 **Evidence before this study** 39 We searched PubMed for studies published through Nov 3, 2021 on the Delta (B.1.617.2) SARS-CoV-2 variant that focused on three areas: 1) transmissibility [search terms: ("Delta variant" OR 40 41 "B.1.617") AND ("transmission rate" OR "growth rate" OR "secondary attack rate" OR 42 "transmissibility")]; 2) immune response ([search terms: ("Delta variant" OR "B.1.617") AND ("immune evas" OR "immune escape")]; and 3) vaccine effectiveness ([search terms: ("Delta 43 variant" OR "B.1.617") AND ("vaccine effectiveness" OR "vaccine efficacy" OR "vaccination")]. 44 45 Our search returned 256 papers, from which we read the abstracts and identified 54 relevant 46 studies. 47 48 Forty-two studies addressed immune evasion and/or vaccine effectiveness. Around half (n=19) 49 of these studies measured the neutralizing ability of convalescent sera and/or vaccine sera 50 against Delta and most reported some reduction (around 2- to 8-fold) compared to ancestral variants. The remainder (n=23) used field observations (often with a test-negative or cohort-51 52 design) and reported lower VE against infection but similar VE against hospitalization or death. 53 Together, these laboratory and field observations consistently indicate that Delta can evade preexisting immunity. In addition, five studies reported higher B-cell and/or T-cell vaccine-54 55 induced immune response among recovered vaccinees than naïve vaccinees, suggesting 56 potential boosting of pre-existing immunity; however, all studies were based on small samples 57 (n = 10 to 198 individuals).

#### 58

59 Sixteen studies examined transmissibility, including 1) laboratory experiments (n=6) showing 60 that Delta has higher affinity to the cell receptor, fuses membranes more efficiently, and/or 61 replicates faster than other SARS-CoV-2 variants, providing biological mechanisms for its higher 62 transmissibility; 2) field studies (n=5) showing higher rates of breakthrough infections by Delta 63 and/or higher viral load among Delta infections than other variants; and 3) modeling/mixed studies (n=5) using genomic or case data to estimate the growth rate or reproduction number, 64 65 reporting a 60-120% increase. Only one study jointly estimated the increase in transmissibility 66 (1.3-1.7-fold, 50% CI) and immune evasion (10-50%, 50% CI); this study also reported a 27.5% (25/91) reinfection rate by Delta. 67

68

# 69 Added value of this study

70 We utilize observed pandemic dynamics and the differential vaccination coverage for two 71 vaccine doses in India, where the Delta variant was first identified, to estimate the 72 epidemiological properties of Delta and examine the impact of prior non-Delta infection on 73 immune boosting at the population level. We estimate that Delta variant can escape immunity 74 from prior wildtype infection roughly one-third of the time and is around 60% more infectious 75 than wildtype SARS-CoV-2. In addition, our analysis suggests the large increase in population 76 receiving their first vaccine dose (~50% by end of Oct 2021) combined with the boosting effect 77 of vaccination for non-Delta infection recoverees likely mitigated epidemic intensity in India during July – Oct 2021. 78

79

#### 80 Implications of all the available evidence

81 Our analysis reconstructs the interplay and effects of non-pharmaceutical interventions,

- 82 infection seasonality, Delta variant emergence, and vaccination on COVID-19 pandemic
- 83 dynamics in India. Modeling findings support prioritizing the first vaccine dose in populations
- 84 with high prior infection rates, given vaccine shortages.
- 85
- 86

#### 87 INTRODUCTION

The Delta (PANGO lineage: B.1.617.2) SARS-CoV-2 variant of concern (VOC)<sup>1-4</sup> has spread 88 89 quickly to over 170 countries (GISAID,<sup>5</sup> as of 11/3/2021). Several lines of evidence have 90 indicated that Delta is able to evade immunity from prior infection by preexisting variants; these include reduced neutralizing ability of convalescent sera and vaccinee sera against 91 Delta,<sup>6-9</sup> reduced vaccine effectiveness (VE) against infection,<sup>10-13</sup> and reduced VE against 92 symptomatic disease after 1-dose of vaccine (but only slight reduction for full vaccination).<sup>14-16</sup> 93 In addition, studies have found a higher secondary attack rate, growth rate, or reproduction 94 95 number for Delta than prior variants including Alpha (range of the mean estimates: 60-96 120%).<sup>2,17-21</sup> In particular, a recent study, fitting a model to mortality data in Delhi, India, 97 estimated a 1.3-1.7-fold (50% CI) increase in transmissibility and 10-50% (50% CI) immune evasion for Delta; however, the authors noted large uncertainty in their estimates.<sup>22</sup> Further, 98 99 factors such as host behavioral changes and seasonal modulation of risk due to changes in 100 environmental conditions are difficult to account for and could confound these estimates. As a 101 result, estimates of prior immunity evasion and relative transmissibility for Delta and the 102 contributions of these properties to the rapid spread of this variant remain uncertain. 103

104 India, where Delta was first identified, experienced an intensive pandemic wave in late March 105 2021. However, unlike many places seeing a prolonged Delta pandemic wave, the Delta wave in 106 India only lasted 3 months and declined rapidly after peaking mid-May. Since June 2021 cases 107 have remained low. A high infection rate after the Delta wave has been cited as a reason for 108 this dramatic epidemic decline, as vaccination coverage was low at the time (4.2% fully 109 vaccinated at the end of June 2021). However, given an estimated basic reproduction number 110  $(R_0)$  of 6-7,<sup>20</sup> roughly 83-86%  $(1 - 1/R_0)$  of the population would need immunity for the Delta epidemic to subside. Assuming 10-50% immunity escape<sup>22</sup> and a 25-35% infection rate prior to 111 112 the Delta wave,<sup>23</sup> this implies that 53-73% of India's 1.4 billion people would have been infected 113 by Delta within the span of 3 months, despite a national lockdown at the time. 114

To better understand COVID-19 pandemic dynamics in India and the epidemiological 115 116 characteristics of Delta, here we utilize a model-inference method recently developed for SARS-117 CoV-2 VOCs. The model-inference method incorporates epidemiological, population mobility, 118 and weather data to model SARS-CoV-2 transmission dynamics, while accounting for case 119 under-ascertainment, impacts of non-pharmaceutical interventions (NPIs) and vaccination, infection seasonality, and new variants.<sup>24</sup> Applying this method, we have jointly estimated the 120 immune escape potential and change in transmissibility for Alpha, Beta, and Gamma, 121 separately, using data from countries where these three VOCs were first reported.<sup>24</sup> In 122 123 addition, several laboratory studies have reported stronger vaccine-induced immune responses 124 among recovered vaccinees than naïve vaccinees, suggesting potential boosting of pre-existing 125 immunity. In India, while only 23% of the population have received two vaccine doses, 53% 126 have received their first vaccine dose, as of the end of Oct 2021. This large discrepancy in one-127 and two dose coverage, combined with a likely high population infection rate, offers an 128 opportunity to examine the boosting effect of prior non-Delta infection on vaccine-induced 129 immunity at the population level. Therefore, in this study, we first reconstruct the pandemic 130 dynamics in India during March 2020 – June 2021 and estimate key epidemiological 131 characteristics of Delta. We then further use our model estimates to retrospectively predict 132 cases and deaths during July – Oct 2021, under various vaccination and VE scenarios, and 133 compare these simulations to observations in order to estimate the impact of vaccination and 134 VE for those with prior non-Delta infection.

135

#### 136 METHODS

#### 137 Data sources and processing

138 We used reported COVID-19 case and mortality data to capture transmission dynamics,

139 weather data to estimate infection seasonality, mobility data to represent concurrent NPIs, and

- 140 vaccination data to account for changes in population susceptibility due to vaccination in the
- 141 model-inference system. COVID-19 case and mortality data from the week of March 8, 2020
- 142 (the first week COVID-19 deaths were reported in India) to the week of Oct 17, 2021 came from
- 143 the COVID-19 Data Repository of the Center for Systems Science and Engineering (CSSE) at

- 144 Johns Hopkins University.<sup>25,26</sup> Surface station temperature and humidity data were accessed
- using the "rnoaa" R package.<sup>27</sup> We then aggregated these data for all weather stations in India
- 146 (n = 390 stations) with measurements from Jan 2020 to Oct 2021 and calculated the average for
- 147 each week of the year. Mobility data were derived from Google Community Mobility Reports;<sup>28</sup>
- 148 we aggregated all business-related categories (i.e., retail and recreational, transit stations, and
- 149 workplaces) in all locations in India to weekly intervals. Vaccination data (1<sup>st</sup> and 2<sup>nd</sup> dose) were
- 150 obtained from Our World in Data.<sup>29,30</sup>
- 151

# 152 Model-inference system

153 The model-inference system was developed and described in detail in our previous study.<sup>31</sup>

- 154 Below we describe each component in brief.
- 155
- 156 Epidemic model
- 157 The epidemic model follows an SEIRSV (susceptible-exposed-infectious-recovered-susceptible-
- 158 vaccination) construct per Eqn 1:

$$\begin{cases} \frac{dS}{dt} = \frac{R}{L_t} - \frac{b_t e_t m_t \beta_t IS}{N} - \varepsilon - v_{1,t} - v_{2,t} \\ \frac{dE}{dt} = \frac{b_t e_t m_t \beta_t IS}{N} - \frac{E}{Z_t} + \varepsilon \\ \frac{dI}{dt} = \frac{E}{Z_t} - \frac{I}{D_t} \\ \frac{dR}{dt} = \frac{I}{D_t} - \frac{R}{L_t} + v_{1,t} + v_{2,t} \end{cases}$$

159

160 where S, E, I, R are the number of susceptible, exposed (but not yet infectious), infectious, and

161 recovered/immune/deceased individuals; N is the population size; and  $\varepsilon$  is the number of

travel-imported infections. In addition, the model includes the following key components:

163 1) Virus-specific properties, including the time-varying variant-specific transmission rate 164  $\beta_t$ , latency period  $Z_t$ , infectious period  $D_t$ , and immunity period  $L_t$ . Note the subscript, t, denotes 165 time in week, as all parameters are estimated for each week as described below.

166 2) The impact of NPIs. Specifically, we use relative population mobility (see data above) 167 to adjust the transmission rate via the term  $m_t$ . To further account for potential changes in 168 effectiveness, the model additionally includes a parameter,  $e_t$ , to scale NPI effectiveness.

169 3) The impact of vaccination, via the terms  $v_{1,t}$  and  $v_{2,t}$ . Specifically,  $v_{1,t}$  is the number of

170 individuals successfully immunized after the first dose of vaccine and is computed using

171 vaccination data and vaccine efficacy for  $1^{st}$  dose; and  $v_{2,t}$  is the additional number of

individuals successfully immunized after the second vaccine dose (i.e., excluding those

173 successfully immunized after the first dose).

4) Infection seasonality, computed using temperature and specific humidity data as
described previously (see supplemental material of Yang and Shaman<sup>24</sup>). The estimated relative
seasonal trend, b<sub>t</sub>, is used to adjust the relative transmission rate at time t.

177

# 178 Observation model to account for under-detection and delay

179 Using the model-simulated number of infections occurring each day, we further computed the number of cases and deaths each week to match with the observations, as done in Yang et al.<sup>32</sup> 180 181 For example, for case data, we include 1) a time-lag from infectiousness to detection (i.e., an 182 infection being diagnosed as a case) to account for delays in detection; and 2) an infection-183 detection rate  $(r_t)$ , i.e. the fraction of infections (including subclinical or asymptomatic 184 infections) reported as cases, to account for under-detection. To compute the model-simulated 185 number of new cases per week, we multiply the model-simulated number of new infections per 186 day by the infection-detection rate, and further distribute these simulated cases in time per the 187 distribution of time-from-infectiousness-to-detection. We then aggregate the daily lagged, 188 simulated cases to weekly totals for model inference (see below).

189

# 190 Model inference and parameter estimation

191 The inference system uses the EAKF,<sup>33</sup> a Bayesian statistical method, to estimate model state

variables (i.e., *S*, *E*, *I*, *R* from Eqn 1) and parameters (i.e.,  $\beta_t$ ,  $Z_t$ ,  $D_t$ ,  $L_t$ ,  $e_t$ , from Eqn 1 as well as  $r_t$ 

and other parameters from the observation model). Briefly, the EAKF uses an ensemble of

194 model realizations (*n*=500 here), each with initial parameters and variables randomly drawn

from a *prior* range (see Table S1). After model initialization, the system integrates the model ensemble forward in time for a week (per Eqn 1) to compute the prior distribution for each model state variable and parameter, as well as the model-simulated number of cases and deaths for that week. The system then combines the prior estimates with the observed case and death data for the same week to compute the posterior per Bayes' theorem.<sup>33</sup> During this filtering process, the system updates the posterior distribution of all model variables and parameters for each week.

202

203 Estimating the immune escape potential and changes in transmissibility for Delta 204 To identify the most plausible combination of changes in transmissibility and level of immune evasion, per methods developed in ref<sup>24</sup>, we ran the model-inference, repeatedly and in turn, 205 206 to test 14 major combinations of these two quantities and select the best performing run. 207 Based on the best-performing model estimates, we then computed the variant-specific 208 transmissibility as the product of the variant-specific transmission rate ( $\beta_t$ ) and infectious 209 period  $(D_t)$ . To reduce uncertainty, we averaged transmissibility estimates over the first 210 pandemic wave and the period when Delta is dominant, separately. We then computed the 211 average change in transmissibility due to Delta as the ratio of the two averaged estimates (i.e., 212 after: before the rise of Delta). To quantify immune evasion, we recorded the changes in 213 susceptibility over time and then computed the level of immune evasion as the ratio of the 214 total increase in susceptibility due to immune evasion during the second wave to the model-215 estimated population immunity at the end of the first wave.

216

To account for model stochasticity, we repeated the model-inference process 300 times, each with 500 model realizations and summarized the results from all 150,000 model estimates. As a sensitivity test and part of the effort to examine the impact of prior non-Delta infection on VE, we performed the analysis using 12 different VE settings (see details below).

221

222 Model validation using independent data

223 To compare model estimates with independent observations not assimilated into the model-224 inference system, we identified three measurements of cumulative infection rates from three 225 nationwide serology surveys in India: i) the first national serosurvey conducted during May 11 – June 4, 2020 (n = 28,000 adults 18 years or older);<sup>34</sup> ii) the second national serosurvey 226 227 conducted during August 18 – September 20, 2020 (n = 29,082 individuals 10 years or older);<sup>35</sup> 228 and iii) the third national serosurvey conducted during December 18, 2020 – January 6, 2021 (n = 28,598 individuals 10 years or older).<sup>36</sup> To account for the delay in antibody generation, we 229 shifted the timing of each serosurvey 14 days when comparing survey results to model-230 231 inference system estimates of cumulative infection rates in Fig 1B.

232

# 233 Estimating the impact of vaccination and prior non-Delta infection on boosting vaccine-

# 234 induced immunity

235 We generated retrospective projections of cases and deaths from the week starting 7/4/2021236 to the week starting 10/17/2021 (i.e., 16 weeks following the model-inference period), under 237 various vaccination and VE settings. We considered four levels of VE for those recovered from 238 non-Delta infection: 1) No boosting effect, i.e., using the same VE values as those without prior 239 infection. Here, we set VE at fourteen days after the 1<sup>st</sup> dose (VE1) to 30% and at seven days after the 2<sup>nd</sup> dose (VE2) to 67%, based on data for the AstraZeneca vaccine against Delta;<sup>15</sup> 2) 240 Higher VE for the 1<sup>st</sup> dose but no future boosting for the 2<sup>nd</sup> dose (here, VE1 is set to 40%, 50%, 241 or 60%, and VE2 fixed at 67%); 3) Higher VE for the 2<sup>nd</sup> dose but not 1<sup>st</sup> dose (here, VE1 is fixed 242 243 at 30% and VE2 set to 75%, 85%, or 95%); and 4) Higher VE for both doses (here, VE1/VE2 are 244 set to 50%/75%, 60%/80%, 70%/85%, 80%/90%, or 90%/95%). To test the impact of 245 vaccination, in addition to projections using reported vaccination rates, we also generated 246 counterfactual projections assuming no further vaccination during the 16-week period. 247 248 For all projections, the model was initiated using model-inference estimates made at the week 249 of 6/27/2021, except for the infection-fatality risk (IFR). For IFR, estimates were decreasing

during June 2020 (Fig S1B) and model-inference extended to the end of July 2021 showed

251 continued decreases, likely due to improved healthcare and increased protection from prior

252 infection or vaccination. We thus assumed that IFR would decrease linearly for the first 6 weeks 253 of the projection period and then flatten and remain at that low IFR until the week of 254 10/17/2021. To account for NPIs, we used mobility data during the week of 7/4/2021 – the 255 week of 10/17/2021. As for the model-inference runs, we repeated the projections for each 256 scenario 300 times (each with 500 model realizations) and summarized the projections from all 257 runs. To evaluate the projection accuracy, we computed the relative root-mean-square-error (RRMSE) and correlation between the projected and observed values for cases and deaths, 258 259 respectively.

260

### 261 **RESULTS**

#### 262 The first COVID-19 pandemic wave in India, March 2020 – January 2021

263 From March 2020 to January 2021 India recorded over 10 million COVID-19 cases (0.77% of its 264 population); however, a nationwide serology survey suggested that ~24% of its population had been infected by December 2020.<sup>23</sup> Accounting for under-detection of infection (Fig S1), 265 266 implemented non-pharmaceutical interventions (NPIs), seasonality, and vaccination, we used 267 the model-inference system to reconstruct pandemic dynamics in India since March 2020 (Fig 1A). Model-estimated infection rates closely match with measurements from three nationwide 268 269 serologic surveys conducted during the early, mid, and late phases of the first pandemic wave 270 (Fig 1B). Our analysis indicates that the 2-month long national lockdown (March 24 – May 31, 271 2020) and the less favorable weather conditions during pre-monsoon season (i.e., March – 272 May) likely contributed to initial low infection rates. By mid-May 2020, the model-inference 273 system estimates that only 0.43% (95% CrI: 0.19 - 1.7%) of the population had been infected 274 [vs. 0.73% (95% CI: 0.34%, 1.13%) among adults estimated by serosurvey<sup>34</sup>]. As the country 275 lifted its lockdown in June 2020 and entered the monsoon season (June – September), when 276 conditions are likely more favorable for transmission (Fig 1C), the first pandemic wave began. 277 Nevertheless, continued regional restrictions during June – November 2020 and less favorable 278 weather conditions during the autumn (October – November; see mobility and seasonal trends 279 in Fig 1C) likely mitigated pandemic intensity. The estimated mean of the reproduction number 280  $R_t$  (i.e., average number of secondary infections per primary infection) was above 1 but less

than 1.35 from June to mid-September; in addition, Rt dropped below 1 during October –

282 November (Fig 1D). By the end of January 2021 when case rates reached a minimum following

the first wave, the model-inference system estimates that 26.1% (95% CrI: 19.9 – 33.0%) of the

284 population had been infected (Fig 1B).

285

# 286 The second pandemic wave in India and estimated epidemiological characteristics of Delta

287 Infections resurged dramatically in late March 2021, largely due to the rise of the Delta variant.

288 Despite a weeks-long second national lockdown implemented beginning April 20, 2021, India

reported another 19 million cases during late March – June 2021, about twice the number

reported during the previous 12 months. Accounting for under-detection (Fig S1), we estimate

that 32.3% (95% CrI: 22.4 – 46.5%) of the population were infected during this 3-month period,

292 including reinfections. This intense transmission was likely facilitated by the higher

transmissibility and immune evasive capabilities of the Delta variant. Estimated transmissibility

increased substantially during the second pandemic wave (Fig 1E). In addition, estimated

295 population susceptibility increased at the start of the second pandemic wave (Fig 1F),

suggesting loss of population immunity against Delta. Due to this immune escape, an estimated

297 50.5% (95% Crl: 21.8 – 79.0%) of the population remained susceptible at the end of June 2021,

despite two large pandemic waves and rollout of mass vaccination (of note, 19% of the

299 population had received at least 1 dose of vaccine by the end of June 2021). These findings

along with the seasonal trends described above suggest that the decline of the second wave

301 was largely due to the NPIs implemented and less favorable weather conditions during March –

302 May, rather than high population immunity.

303

Combining the model-inference estimates during the first and second pandemic waves in India,
we estimated that Delta was able to escape immunity among 34.6% (95% CI: 0 – 64.2%) of

individuals with prior wildtype infection and was 57.0% (95% CI: 37.9 – 75.6%) more

307 transmissible than wildtype SARS-CoV-2. Estimates are similar under different VE settings (Fig

308 S2).

309

#### 310 Impact of vaccination and prior non-Delta infection on boosting vaccine-induced immunity

311 Despite the likely conducive conditions during the monsoon season (June – September), easing 312 of NPIs, and relatively high susceptibility estimated at the end of June 2021, cases and deaths in 313 India remained at relatively low levels during July – Oct 2021. Counterfactual modeling suggests 314 that the faster rollout of vaccination during this period substantially mitigated the epidemic risk 315 (Fig 2). Projected cases and deaths assuming no further vaccination uptake are much higher than observed; In contrast, models including the reported vaccination rates more closely match 316 317 reported cases and deaths (Fig 2). Further, models assuming higher VE for non-Delta infection 318 recoverees generated more accurate projections than those assuming no boosting effect (Fig 319 3). The boosting effect appears to be more pronounced for the 1<sup>st</sup> vaccine dose (see, e.g., Fig 3A 320 where larger dots, representing higher VE after the 1<sup>st</sup> dose, had smaller errors). Overall, the model assuming 90%/95% VE for the 1<sup>st</sup>/2<sup>nd</sup> dose of vaccine for non-Delta infection recoverees 321 322 generated the most accurate projections. These projections estimate that vaccination rollout 323 combined with the boosting effect averted 57% of infections during July – mid-Oct 2021.

324

# 325 Discussion

Combining epidemiological, behavioral, and weather observational data with a comprehensive
 model-inference system, we estimate the Delta SARS-CoV-2 variant escaped immunity in
 roughly one-third of individuals with wildtype infection during the previous year and was
 around 60% more infectious than wildtype SARS-CoV-2. In addition, our analysis suggests the
 large increase in population receiving their first vaccine dose (~50% by end of Oct 2021)
 combined with the boosted VE for non-Delta infection recoverees likely mitigated the epidemic
 intensity in India in recent months.

333

Previously, we have estimated the changes in transmissibility and immune escape potential for
three other major SARS-CoV-2 VOCs: namely, a 46.6% (95% CI: 32.3 – 54.6%) increase in
transmissibility but nominal immune escape for Alpha (i.e., B.1.1.7), a 32.4% (95% CI: 14.6 –
48.0%) increase in transmissibility and 61.3% (95% CI: 42.6 – 85.8%) immune escape for Beta
(i.e., B.1.351), and a 43.3% (95% CI: 30.3 – 65.3%) increase in transmissibility and 52.5% (95%

339 CI: 0 – 75.8%) immune escape for Gamma (i.e., P.1). Compared with Alpha, data from the UK 340 have shown that the secondary attack rate for contacts of cases with Delta was around 1.5 341 times higher than Alpha (12.4% vs. 8.2%), during March 29 – May 11, 2021.<sup>2</sup> In a partially 342 immunized population, the secondary attack rate reflects the combined outcome of the 343 transmissibility of the etiologic agent and population susceptibility to that agent. Consistent 344 with the UK data, our estimates of the relative transmissibility and immune escape potential combine to a 44.1% (95% CI: 4.2 – 86.6%) higher secondary attack rate by Delta than Alpha [i.e., 345 346  $(1+57\%)/(1+46.6\%) \times (1+34.6\%) - 1 = 44.1\%$  increase]. This higher competitiveness of Delta 347 over Alpha explains the rapid variant displacement observed in regions previously dominated by Alpha (e.g. the UK and the US). 348

349

350 In addition, we estimate that 34.6% (95% CI: 0 - 64.2%) of individuals with acquired immunity 351 from wildtype infection would be susceptible to Delta due to immune escape. This estimate is also in line with a recent study<sup>22</sup> reporting a 27.5% reinfection rate during the Delta pandemic 352 353 wave in Delhi, India, based on a small subset of people with repeated serology measures. In 354 addition to immune escape from wildtype infection, studies have also reported reduced ability 355 of sera from Beta- and Gamma-infection recoverees to neutralize Delta,<sup>8,37</sup> suggesting Delta can 356 also escape immunity conferred by those two VOCs. Such immune escape ability would also 357 allow Delta to rapidly replace Beta and Gamma in regions previously hard-hit by those two VOCs, as has been observed in many countries in Africa and South America.<sup>5</sup> More 358 359 fundamentally, these findings highlight the complex, non-linear immune landscape of SARS-360 CoV-2 and the importance to monitor the immune escape potential of new variants against 361 both previous and concurrent circulating variants.

362

Despite the successful development of multiple vaccines, shortage of supplies – particularly in
 resource-limited countries – remains an impediment to global mass vaccination.<sup>38</sup> In response,
 researchers have proposed dose sparing strategies such as fractionation<sup>39</sup> and 1-dose
 vaccination for recoverees.<sup>40</sup> The latter 1-dose strategy draws on laboratory studies showing
 higher vaccine-induced immune response among recovered vaccinees than naïve vaccinees

(i.e., boosting of pre-existing immunity).<sup>41-44</sup> Here, we utilized model-inference estimates and
vaccination data in India to test the impact of boosting at the population level. The findings
further support the effectiveness of 1-dose vaccination for recoverees. In light of continued
vaccine shortages, prioritizing first-dose vaccination thus may be an effective strategy for
mitigating COVID-19 burden in countries with high underlying SARS-CoV-2 infection rates.

374 Due to a lack of detailed epidemiological data (e.g., age-specific and subnational) and thus 375 model simplification, our estimates have uncertainties as indicated by the large credible 376 intervals. Nevertheless, these estimates are in line with independent data from three 377 nationwide serology surveys conducted at three time points during the first pandemic wave in 378 India (Fig 1B), as well as Delta-related epidemiological data from the UK<sup>2</sup> and Delhi, India,<sup>22</sup> as 379 discussed above; these consistencies support the accuracy of our estimates. Unlike estimates 380 from the contact tracing data, however, here we are able to separately quantify the changes in 381 transmissibility and immune escape potential of the Delta variant. In addition, our analysis also 382 suggests high 1-dose vaccine effectiveness among those with prior infection. These findings 383 and the methods used to generate them could support better understanding of future SARS-384 CoV-2 variant dynamics given local prior infection rates, variant prevalence, and vaccination 385 coverage.

386

387 Data Availability: All data used in this study are publicly available as described in the "Data
388 sources and processing" section.

389

390 Code availability: All source code and data necessary for the replication of our results and
391 figures are made publicly available at https://github.com/wan-yang/covid\_voc\_delta.

392

**Acknowledgements**: This study was supported by the National Institute of Allergy and

394 Infectious Diseases (AI145883 and AI163023), the National Science Foundation Rapid Response

Research Program (RAPID; DMS-2027369) and a gift from the Morris-Singer Foundation.

396

- **Author contributions**: WY designed the study, performed the analysis, and wrote the first draft;
- 398 JS provided input to the analysis and contributed to the final draft.
- 399
- 400 **Competing interests**: JS and Columbia University disclose partial ownership of SK Analytics. JS
- 401 discloses consulting for BNI.

### 402 **References**:

- 403 1. World Health Organization. Tracking SARS-CoV-2 variants. 2021.
- 404 <u>https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</u>.
- 405 2. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in
- 406 England. Technical briefing 14. 2021.
- 407 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachmen</u>
- 408 <u>t data/file/991343/Variants of Concern VOC Technical Briefing 14.pdf</u> (accessed
  409 6/16/2021 2021).
- 410 3. National Collaborating Centre for Infectious Diseases. Updates on COVID-19 Variants of
- 411 Concern. 4/26/2021 2021. <u>https://nccid.ca/covid-19-variants/</u> (accessed 5/3/2021 2021).
- 412 4. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and
- 413 Definitions. 2021. <u>https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html</u>
  414 (accessed 6/17/2021 2021).
- 415 5. Global Initiative on Sharing All Influenza Data (GISAID). Tracking of Variants. 6/16/2021
  416 2021. https://www.gisaid.org/hcov19-variants/ (accessed 6/16/2021 2021).
- 417 6. Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and
  418 immune evasion. *Nature* 2021.
- 419 7. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs
- 420 B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet* 2021.
- 421 8. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by
  422 vaccine and convalescent serum. *Cell* 2021; **184**(16): 4220-+.

- 423 9. Arora P, Sidarovich A, Krüger N, et al. B.1.617.2 enters and fuses lung cells with increased
  424 efficiency and evades antibodies induced by infection and vaccination. *Cell Reports* 2021;
  425 **37**(2): 109825.
- 426 10. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against
  427 SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021.
- 428 11. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in
  429 Israel. *N Engl J Med* 2021.
- Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines
   for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv* 2021:
- 432 2021.08.06.21261707.
- 433 13. Elliott P, Haw D, Wang H, et al. Exponential growth, high prevalence of SARS-CoV-2, and
  434 vaccine effectiveness associated with the Delta variant. *Science* 2021: eabl9551.
- 435 14. Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the
  436 B.1.617.2 variant. *medRxiv* 2021: 2021.05.22.21257658.
- 437 15. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the
- 438 B.1.617.2 (Delta) Variant. *New England Journal of Medicine* 2021; **385**(7): 585-94.
- 439 16. Seppala E, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the Delta
  440 (B.1.617.2) variant, Norway, April to August 2021. *Eurosurveillance* 2021; **26**(35).
- 441 17. Allen H, Vusirikala A, Flannagan J, et al. Household transmission of COVID-19 cases
- 442 associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study. *The*443 *Lancet regional health Europe* 2021: 100252.
- 444 18. Challen R, Dyson L, Overton CE, et al. Early epidemiological signatures of novel SARS-CoV2 variants: establishment of B.1.617.2 in England. *medRxiv* 2021: 2021.06.05.21258365.
- 446 19. Earnest R, Uddin R, Matluk N, et al. Comparative transmissibility of SARS-CoV-2 variants
  447 Delta and Alpha in New England, USA. *medRxiv* 2021.
- Vohringer HS, Sanderson T, Sinnott M, et al. Genomic reconstruction of the SARS-CoV-2
  epidemic in England. *Nature* 2021.
- 21. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global
  spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance* 2021; 26(24).

- 452 22. Dhar MS, Marwal R, Vs R, et al. Genomic characterization and epidemiology of an
- 453 emerging SARS-CoV-2 variant in Delhi, India. *Science* 2021: eabj9932.
- 454 23. Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. SARS-CoV-2 seroprevalence among the
- 455 general population and healthcare workers in India, December 2020–January 2021. Int J
- 456 Infect Dis 2021; **108**: 145-55.
- 457 24. Yang W, Shaman J. Development of a model-inference system for estimating
- 458 epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature*
- 459 *Communications* 2021; **12**: 5573.
- 460 25. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at
- 461 Johns Hopkins University. 2021. <u>https://github.com/CSSEGISandData/COVID-19</u>.
- 462 26. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
  463 time. *Lancet Infect Dis* 2020; **20**(5): 533-4.
- 464 27. Chamberlain S, Anderson B, Salmon M, et al. Package 'rnoaa'. 2021.
- 465 28. Google Inc. Community Mobility Reports. 2020.
  466 https://www.google.com/covid19/mobility/.
- 467 29. Data on COVID-19 (coronavirus) vaccinations by Our World in Data. 2020.
- 468 https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations.
- 30. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations.
  Nat Hum Behav 2021; 5(7): 947-53.
- 471 31. Yang W, Shaman J. Epidemiological characteristics of three SARS-CoV-2 variants of
  472 concern and implications for future COVID-19 pandemic outcomes. *medRxiv* 2021:
- 473 2021.05.19.21257476.
- 474 32. Yang W, Kandula S, Huynh M, et al. Estimating the infection-fatality risk of SARS-CoV-2 in
- 475 New York City during the spring 2020 pandemic wave: a model-based analysis. *The Lancet*476 *Infectious diseases* 2021; **21**(2): 203-12.
- 477 33. Anderson JL. An ensemble adjustment Kalman filter for data assimilation. *Mon Weather*478 *Rev* 2001; **129**(12): 2884-903.

- 479 34. Murhekar MV, Bhatnagar T, Selvaraju S, et al. Prevalence of SARS-CoV-2 infection in India:
- 480 Findings from the national serosurvey, May-June 2020. *Indian J Med Res* 2020; **152**(1): 48481 57.
- 482 35. Murhekar MV, Bhatnagar T, Selvaraju S, et al. SARS-CoV-2 antibody seroprevalence in
- 483 India, August-September, 2020: findings from the second nationwide household
- 484 serosurvey. *The Lancet Global Health* 2021; **9**(3): e257-e66.
- 485 36. Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. SARS-CoV-2 seroprevalence among the
- 486 general population and healthcare workers in India, December 2020 January 2021. Int J
  487 Infect Dis 2021; 108: 145-55.
- 488 37. de Oliveira T, Lessells R. Update on Delta and other variants in South Africa and other
- 489 world. 2021. <u>https://www.krisp.org.za/manuscripts/DeltaGammaSummary\_NGS-</u>
  490 SA 6JulV2.pdf.
- 38. Padma TV. COVID vaccines to reach poorest countries in 2023 despite recent pledges.
  7/5/2021 2021. <u>https://www.nature.com/articles/d41586-021-01762-w</u> (accessed
  11/11/2021 2021).
- 494 39. Cowling BJ, Lim WW, Cobey S. Fractionation of COVID-19 vaccine doses could extend
  495 limited supplies and reduce mortality. *Nature Medicine* 2021; 27(8): 1321-3.
- 496 40. Sasikala M, Shashidhar J, Deepika G, et al. Immunological memory and neutralizing activity
- 497 to a single dose of COVID-19 vaccine in previously infected individuals. *International*498 *Journal of Infectious Diseases* 2021; **108**: 183-6.
- 41. Andreano E, Paciello I, Piccini G, et al. Hybrid immunity improves B cells and antibodies
  against SARS-CoV-2 variants. *Nature* 2021.
- 42. Lucas C, Vogels CBF, Yildirim I, et al. Impact of circulating SARS-CoV-2 variants on mRNA
  vaccine-induced immunity. *Nature* 2021.
- 43. Sokal A, Barba-Spaeth G, Fernández I, et al. mRNA vaccination of naive and COVID-19-
- recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. *Immunity* 2021.

- 506 44. Sapkal GN, Yadav PD, Sahay RR, et al. Neutralization of Delta variant with sera of
- 507 Covishield<sup>™</sup> vaccinees and COVID-19-recovered vaccinated individuals. *J Travel Med* 2021;
- 508 **28**(7).
- 509

**Fig 1.** Model-inference estimates and validation. (A) Model fit. (B) Model validation. (C) Observed relative mobility and estimated disease seasonal trend, compared to case and death rates over time. Key model-inference estimates are shown for the real-time reproduction number  $R_t$  (D), transmissibility (E), and population susceptibility (F). Blue lines and surrounding areas show the estimated mean, 50% (dark) and 95% (light) CrIs. Boxes and whiskers show the estimated mean, 50% and 95% CrIs for weekly cases and deaths in (A) and infection rates in (D) – (F). Grey shaded areas indicate the timing of national lockdowns (darker) or local restrictions (lighter); horizontal arrows indicate the timing of variant identification and vaccination rollout. In (C), for mobility (blue line; y-axis), values below 1 (dashed horizontal line) indicate reductions due to public health interventions. For the disease seasonal trend (orange line; y-axis), values above 1 indicate weather conditions more conducive for transmission than the yearly average and *vice versa*. Note that the transmissibility estimates have removed the effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more stable than the reproduction number ( $R_t$ ; left column) and reflect changes in variant-specific properties.



**Fig 2.** Impact of vaccination. Model projections of weekly number of reported cases (A) and reported deaths (B) for India during July – mid-Oct 2021, compared to reported data. Crosses ('x') show reported data (left y-axis). Red dashed lines show median counterfactual model projections assuming no further vaccination uptake during the 16-week period. Blue dashed lines show median model projections using reported vaccination rates and assuming 90%/95% vaccine effectiveness for individuals with prior non-Delta infection after the 1<sup>st</sup>/2<sup>nd</sup> vaccine dose. Shaded areas with the same color show projected interquartile ranges. For comparison, estimated seasonality (orange lines), reported mobility (dark-blue lines), and cumulative vaccination uptake (full bar for 1<sup>st</sup> dose and filled section for 2<sup>nd</sup> dose) are overlaid (see right y-axis scale). All numbers are scaled per one million people.



**Fig 3.** Impact of prior non-Delta infection on immune boosting. Model projections under different vaccine effectiveness (VE) settings are used to examine the most plausible VE for individuals with prior non-Delta infection, based on projection accuracy: (A) the relative root-mean-square-error (RRMSE) and (B) correlation between the projected and observed values for cases and deaths, respectively. The size of the dots represents VE for recoverees after the 1<sup>st</sup> vaccine dose and the color represents VE after the 2<sup>nd</sup> vaccine dose. The dots with the black circles represent the baseline VE setting (i.e. 30%/67% for the 1<sup>st</sup>/2<sup>nd</sup> dose). For comparison, projected weekly numbers of reported cases (C) and reported deaths (D) under different VE settings are plotted along with the weekly actuals. For clarity, only median projections are shown here; see example projections including interquartile ranges in Fig 2.



# Supplemental Table and Figures

**Table S1.** Prior ranges for the parameters used in the model-inference system.

Parameter/ variable	Symbol	Prior range	Source/rationale
Initial exposed	<i>E</i> (t=0)	500 – 1000 times of the reported number of cases on the first week of simulation (i.e. the week of 3/8/2020)	Low infection-detection rate in first weeks.
Initial infectious	/(t=0)	Same as for <i>E</i> (t=0)	
Initial susceptible	<i>S</i> (t=0)	99 – 100% of the population	Almost everyone is susceptible initially
Population size	Ν	N/A	Based on data
Variant-specific transmission rate	в	[0.4, 0.7]	Based on $R_0$ estimates of around 1.5-4 for SARS-CoV-2. <sup>1-3</sup> Slightly lower ranges are used here, as initial testing showed that use of higher values tended to overestimate the observations.
Scaling of effectiveness of NPI	е	[0.5, 1.5]	Around 1, with a large bound to be flexible.

Latency period	Ζ	[2, 5] days	Incubation period: 5.2 days (95% CI: 4.1, 7) <sup>1</sup> ; latency period is likely shorter than the incubation period
Infectious period	D	[2, 5] days	Time from symptom onset to hospitalization: 3.8 days (95% CI: 0, 12.0) in China, <sup>4</sup> plus 1-2 days viral shedding before symptom onset. We did not distinguish symptomatic/asymptomatic infections.
lmmunity period	L	[730, 1095] days	Assuming immunity lasts for 2-3 years
Mean of time from viral shedding to diagnosis	T <sub>m</sub>	[5, 8] days	From a few days to a week from symptom onset to diagnosis/reporting, <sup>4</sup> plus 1-2 days of viral shedding (being infectious) before symptom onset. There may be a slightly longer delay for South Africa and Brazil.
Standard deviation (SD) or time from viral shedding to diagnosis	T <sub>sd</sub> f	[1, 3] days	To allow variation in time to diagnosis/reporting

Infection- detection rate	r	Starting from U[0.0001, 0.02] at time 0 and allowed to increase over time using space re-probing <sup>5</sup> with values drawn from U[0.015, 0.08] starting at week 8 (the week of 4/26/2020), U[0.02, 0.08] starting at week 15 (the week of 6/14/2020), U[0.01, 0.08] starting 1/17/2021 (around the end of the first pandemic wave), U[0.01, 0.05] starting 5/23/2021 (around the end of the Delta wave).	Large uncertainties; therefore, in general we use large prior bounds and large bounds for space re-probing (SR). Note that SR is only applied to 3-10% of the ensemble members and <i>r</i> can migrate outside either the initial range or the SR ranges during EAKF update. In India, due to the younger population age structure, infection detection rates were likely low throughout.
Infection fatality risk (IFR)		Starting from U[0.0001, 0.003] at time 0 and allowed to change over time using space re-probing <sup>5</sup> with values drawn from U[0.0001, 0.0015] starting at week 8 (the week of 4/26/2020), values drawn from U[0.0001, 0.0008] during the week of 7/05/2020 to the week of 3/21/2021 when case fatality risk was lower as computed from the data, values drawn from U[0.0001, 0.0015] starting the week of 4/4/2021 with the rise of Delta, values drawn from U[0.0001, 0.003] starting the week of 5/2/2021 when the healthcare systems began to be overwhelmed, and values drawn from U[0.0001, 0.0005] starting the week of 6/6/2021 when many have been infected or vaccinated and reported cases and deaths declined to low levels.	Based on previous estimates <sup>6</sup> but extend to have wider ranges. Note that SR is only applied to 3-10% of the ensemble members and IFR can migrate outside either the initial range or the SR ranges during EAKF update. In India, due to the younger population age structure, infection fatality risk was likely low throughout.
Vaccine efficacy (VE)		VE = 30% fourteen days after the 1 <sup>st</sup> dose, and 67% seven days after the 2 <sup>nd</sup> dose.	During 1/15/2021 – 6/27/2021, India used the Oxford/AstraZeneca and Covaxin vaccines; during 6/28/2021 – 10/31/2021,

Sputnik V was also used. Here we set the baseline VE based on data for the Oxford/AstraZeneca vaccine.<sup>7</sup>

References:

1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New Engl J Med* 2020.

2. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020; **395**(10225): 689-97.

3. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* 2020; **368**(6490): 489-93.

4. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet Infectious diseases* 2020; **20**(7): 793-802.

5. Yang W, Shaman J. A simple modification for improving inference of non-linear dynamical systems. *arXiv* 2014: 1403.6804.

6. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious diseases* 2020; **20**(6): 669-77.

7. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* 2021; **385**(7): 585-94.

**Fig S1.** Estimated infection-detection rate (A) and infection-fatality risk (B) during each week of the study period. For comparison, estimated weekly infection rates are superimposed in each plot (right y-axis). Blue lines and surrounding areas show model estimated mean, 50% and 95% CrIs. Boxes and whiskers show model-estimated weekly infection rates (mean, 50% and 95% CrIs). Grey shaded boxes indicate the timing of lockdowns (darker) or local restrictions (lighter); horizontal arrows indicate the timing of variant identification and vaccination rollout. *Note that infection-fatality risk estimates were based on reported COVID-19 deaths and may not reflect the true values due to the likely under-reporting of COVID-19 deaths.* 



**Fig S2.** Estimated change in transmissibility and immune escape potential for the Delta variant, using different vaccine effectiveness (VE) settings for those with prior non-Delta infection. The baseline VE (i.e. 30%/67% for the  $1^{st}/2^{nd}$  dose) was used for those without any prior infection; those infected by Delta were assumed to acquire immunity against this variant after recovery (see Eqn 1 in the main text). Twelve VE settings were tested (see x-axis label for VE after  $1^{st}/2^{nd}$  dose). Model-inference was done 300 times (each with 500 ensemble members) for each VE setting. The boxplots summarize the distribution of estimates from the 300 runs: middle bar = median, edges = interquartile range, whiskers = 95% CI, red 'x' = mean.



Scenarios: VE for those with prior widetype infections + 1 dose / 2 doses of vaccine